- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
NATCO Pharma's Q3 FY'26 consolidated revenue was INR 705.4 Cr, with net profit at INR 151.3 Cr (30.7% EBITDA), showing strength from Brazil, Canada, and Middle East without Revlimid. FY'26 guidance projects INR 4,200-4,300 Cr revenue and INR 1,280-1,300 Cr PAT.
Key drivers include anticipated >20% domestic growth from the upcoming semaglutide launch. Management is pursuing 2-3 large acquisitions in emerging markets/brands, utilizing INR 2,500 Cr cash. Adcock Ingram is expected to provide strong quarterly PAT contribution. Crop Health Sciences de-merger is aimed for Oct-Nov. Confident in diversified growth via new launches and market expansion.